Precirix
![Precirix](https://flanders.bio/storage/files/9edde66c-d208-4916-b215-242f2bd2bb70/company_logo-precirix-blauw.png)
Burgemeester Etienne Demunterlaan 3
1090 Brussel (Jette)
BE
Precirix
Foundation date
14/10/2014
Sector
#Biotechnology - TherapeuticsTherapeutic areas
Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.
The company’s lead product, CAM-H2, is being evaluated in a Phase I/II trial targeting metastatic HER2-positive cancer. Patients with tumors that overexpress HER2 can benefit from effective targeted treatments today yet have a poor prognosis when the cancer spreads. CAM-H2 aims to effectively irradiate cancer lesions while sparing healthy tissue, based on its unique technology platform that leverages the favorable tissue distribution of sdAbs.
The company’s technology platform also allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy. In addition to CAM-H2, the company has two product candidates in preclinical stage and is further broadening its platform through research on isotopes, linker technology and combination therapies.
Upcoming events
All events-
1109 '24
The Leuven Protein Aggregation Meeting (2nd edition)
Event by: VIB -
1010 '24
-
0411 '24
BIO-Europe® 2024 - 30th Annual International Partnering Conference
Event by: EBD Group
Latest news
More news-
Antonin (Tony) de Fougerolles appointed as new Chair of etherna
Tuesday July 16th 2024
Read more
-
ONTOFORCE Achieves ISO 27001:2022 Certification: A Milestone in Information Security and Trust
Tuesday July 16th 2024
Read more
-
Ghent University spin-off Trince wins Nature Spinoff Prize
Monday July 15th 2024
Read more
Jobs by Precirix
More jobsMore info?
Ellen Telleir
Communication Coordinator